Atrial fibrillation is a major cause of stroke and thromboembolism, and oral anticoagulation
is the mainstay of prevention. In patients who are poor candidates for long-term anticoagulation,
percutaneous left atrial appendage occlusion (pLAAO) emerged as an alternative stroke
prevention strategy and was approved by the US Food and Drug Administration in 2015.
We aimed to examine trends in procedural volume, resource utilization, and clinical
outcomes of pLAAO from a nationally representative cohort.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart RhythmAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Healthcare Cost & Utilization Project User Support. Overview of the National (Nationwide) Inpatient Sample (NIS).www.hcup-us.ahrq.gov/nisoverview.jspDate accessed: June 30, 2022
U.S. Bureau of Labor Statistics. CPI Inflation Calculator. https://www.bls.gov/data/inflation_calculator.htm. Accessed June 30, 2022.
- Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.Lancet. 2009; 374: 534-542
- Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.J Am Coll Cardiol. 2014; 64: 1-12
- The NCDR Left Atrial Appendage Occlusion Registry.J Am Coll Cardiol. 2020; 75: 1503-1518
Article info
Publication history
Published online: October 14, 2022
Footnotes
Funding Sources: The authors have no funding sources to disclose.
Disclosures: The authors have no conflicts of interest to disclose.
Identification
Copyright
© 2022 Heart Rhythm Society. All rights reserved.